human genome oligonucleotide cgh microarray 4 180 k (Agilent technologies)
Agilent technologies is a verified supplier 
Agilent technologies manufactures this product 
90
Structured Review
Agilent technologies
human genome oligonucleotide cgh microarray 4 180 k
Human Genome Oligonucleotide Cgh Microarray 4 180 K, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+genome+oligonucleotide+cgh+microarray+4+180+k/pm29439846-48-8-7
Average 90 stars, based on 1 article reviews
Human Genome Oligonucleotide Cgh Microarray 4 180 K, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+genome+oligonucleotide+cgh+microarray+4+180+k/pm29439846-48-8-7
Average 90 stars, based on 1 article reviews
human genome oligonucleotide cgh microarray 4 180 k - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Hybridization:Article Title: Diagnostic challenge for the rare lysosomal storage disease: Late infantile GM1 gangliosidosis. Article Snippet: Background: GM1 gangliosidosis is a rare lysosomal storage disorder caused by GLB1 mutations.. Because of its extreme rarity and symptoms that overlap with other neurodegenerative diseases, its diagnosis is sometimes challenging, especially in the late infantile form with less severe phenotype.. We aim to expand the clinical and genetic spectrum of late infantile GM1 gangliosidosis. Microarray:Article Title: Diagnostic challenge for the rare lysosomal storage disease: Late infantile GM1 gangliosidosis. Article Snippet: Background: GM1 gangliosidosis is a rare lysosomal storage disorder caused by GLB1 mutations.. Because of its extreme rarity and symptoms that overlap with other neurodegenerative diseases, its diagnosis is sometimes challenging, especially in the late infantile form with less severe phenotype.. We aim to expand the clinical and genetic spectrum of late infantile GM1 gangliosidosis. |